The subscription period in IRLABS’s rights issue of shares commence today
Today, on 3 July 2025, the subscription period commences in IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) rights issue of shares of series A with preferential rights for existing shareholders up to approximately MSEK 136 (the “Rights Issue”), which was resolved and announced on 24 June 2025. The subscription period for the Rights Issue will run until and including 17 July 2025. However, please note that certain banks and nominees may apply an earlier deadline for subscription. Shareholders are therefore advised to check with their bank or nominee regarding any earlier response deadline that may apply.
Read More >IRLAB carries out SEK 136m rights issue
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.
Presentation at Aktiespararna
Presentation by Kristina Torfgård, CEO, at Aktiespararna (in Swedish), held June 10, 2025.
Read More >